53O_PRPREDICTING RISK FOR LATE METASTASIS: THE PAM50 RISK OF RECURRENCE (ROR) SCORE AFTER 5 YEARS OF ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH HR+ EARLY BREAST CANCER: A STUDY ON 1,478 PATIENTS FROM THE ABCSG-8 TRIAL